VBI Vaccines, Inc. – (NASDAQ:VBIV) CEO Jeff Baxter acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average cost of $3.89 per share, for a total transaction of $38,900.00. Following the completion of the purchase, the chief executive officer now owns 140,646 shares in the company, valued at approximately $547,112.94. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jeff Baxter also recently made the following trade(s):

  • On Tuesday, November 28th, Jeff Baxter bought 15,000 shares of VBI Vaccines stock. The stock was purchased at an average price of $4.75 per share, for a total transaction of $71,250.00.

Shares of VBI Vaccines, Inc. – (VBIV) traded up $0.08 during mid-day trading on Friday, hitting $4.18. 1,223,601 shares of the stock traded hands, compared to its average volume of 252,755. VBI Vaccines, Inc. – has a 1-year low of $3.03 and a 1-year high of $6.60. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. BidaskClub lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday. BMO Capital Markets assumed coverage on shares of VBI Vaccines in a report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity assumed coverage on shares of VBI Vaccines in a report on Wednesday, November 1st. They issued a “buy” rating and a $10.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. VBI Vaccines presently has a consensus rating of “Hold” and a consensus target price of $10.50.

Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System acquired a new stake in VBI Vaccines during the 2nd quarter worth approximately $167,000. Schwab Charles Investment Management Inc. acquired a new stake in VBI Vaccines during the 2nd quarter worth approximately $187,000. Bank of New York Mellon Corp acquired a new stake in VBI Vaccines during the 2nd quarter worth approximately $193,000. Teachers Advisors LLC acquired a new stake in VBI Vaccines during the 2nd quarter worth approximately $195,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in VBI Vaccines during the 2nd quarter worth approximately $262,000. Institutional investors and hedge funds own 20.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/vbi-vaccines-inc-vbiv-ceo-purchases-38900-00-in-stock/1768629.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.